Remo Uherek

Menu
  • Start here
  • Blog
    • Twitter Threads
    • Archive
  • Newsletter
  • Recommendations
    • Books
    • Tools
    • Links
  • About
    • What I’m doing now
    • Contact
Menu

Home › Blog › Idorsia: A High-Potential Biopharmaceutical Company (Investment Thesis)

Idorsia: A High-Potential Biopharmaceutical Company (Investment Thesis)

Is Idorsia the next biotech winner in Europe?

  • The founders have sold their previous company for $30B in cash
  • They now want to do it again, and hold 29% of Idorsia
  • Their insomnia drug has just been approved in the US

Idorsia is a high-potential Swiss biotech company, founded by the same people that built Actelion, a biotech company that was sold to Johnson & Johnson for $30B in cash. Jean-Paul and Martine Clozel now intend to build a second Actelion, but instead of owning just 5%, they now own 29% of the company. Here’s my investment thesis.

Here’s the video:

Here’s the audio:
Download podcast episode

Show notes:

Links:

  • Idorsia website: https://www.idorsia.com/
  • Actelion 2016 financial results: https://www.globenewswire.com/news-release/2017/02/14/916716/0/en/Actelion-announces-excellent-financial-results-for-2016.html
  • 100 baggers video: https://www.youtube.com/watch?v=9JiS3DGPEGs

Here’s a list of all my other investing videos:
https://www.youtube.com/watch?v=9JiS3DGPEGs&list=PL3q6QaeUG5KWXlohLeuc150jPyZpyEPv_

Idorsia is a Swiss biopharmaceutical company specializing in the discovery and development of small molecules to meet critical medical needs. Jean-Paul, CEO, and Martine, Chief Scientist, with a powerful pipeline and a world-class R&D engine, aim to build Idorsia into a leading biopharmaceutical company and bring more innovative medicines to patients in need. Idorsia’s goal is to discover the development and commercialization of innovative medicines to help more patients. To do this, they aim to transform Idorsia into a leading biopharmaceutical company with a strong scientific core.

image_pdfPDF
  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)

Related

Tags: Actelion, Basel, Biotech, Idorsia, Investing, Jean-Paul Clozel, Martine Clozel, Stock investing, Switzerland, Video, YouTube
Category: Wealth



January 20, 2022January 20, 2022 by Remo Uherek

Search

⚡  Learn & Grow

Join 1500+ subscribers to receive updates on personal growth, mental health and financial freedom:

Bonus: After signing up, you will receive my exclusive Good Life Checklist with actionable ideas on how to improve your life.

Recent Posts

  • Key Takeaways from Tesla Q4 2022 Earnings
  • My Portfolio Declined -59% in 2022. Here’s What I Learned.
  • Why You Should Die With Zero Money
  • Full Recording: Elon Musk Live on Twitter Spaces Talking Twitter Financials with George Hotz
  • Will Germany’s car industry survive? A deep dive with Tesla expert Alex Voigt

Categories

  • Health
  • Wealth
  • Love
  • Happiness

Archives

  • Archive

Newsletter

Twitter

YouTube

Podcast (Apple, Google, Spotify)

Training Programs